AUTHORS
Zeeshan Solangi, MD, Mutaz Abualshar, MD2, Amirta Devi, MD3, Tornike Zabakhidze, MD4, Ahda Solangi5, Kashif Ali Raza Memon, MD6, Yasmeen Baloch, MD7, Ahmed Abbasi8, Ranjeet Kumar9, Katherin Medical Zambrano, MD10, Ghulam Shah, MD11, Darren Evanchuk, MD12
AFFILIATIONS
1 Dana Farber Cancer Institute at BMC Brighton, Boston, Massachusetts, United States
2 Dana Farber Cancer Institute at BMC Brighton, Boston, Massachusetts, United States
3 Luminis health, Annapolis, United States
4 Boston Medical Center Brighton, Boston, United States
5 Boston Medical Center Brighton, Boston, United States
6 Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
7 Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
8 Berkshire Medical Center, Pittsfield, United States
9 Memorial Healthcare System, Hollywood, Florida, United States
10 Berkshire Medical Center, Pittsfield, United States
11 One Brooklyn Health-Brookdale University Hospital Medical Center, New York, United States
12 Dana Farber Cancer Institute, Boston, United States
ABSTRACT
Background
Teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific T-cell engager, has demonstrated durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). The ongoing phase 3 MajesTEC-9 trial is evaluating teclistamab-based combinations against standard pomalidomide- and carfilzomib-containing regimens in earlier lines of therapy, but comparative real-world data remain limited. We compared the effectiveness and safety of teclistamab with standard pomalidomide- or carfilzomib-based regimens in patients with RRMM using a large multinational electronic health record database.
Methods
We performed a retrospective propensity score-matched cohort study using the TriNetX Global Collaborative Network. Adults with RRMM treated between January 2021 and August 2026 were identified. Patients receiving teclistamab were compared with a control cohort treated with pomalidomide-bortezomib-dexamethasone (PVd) or carfilzomib-based regimens. One-to-one propensity score matching was performed to balance baseline demographics, clinical characteristics, and major comorbidities. The primary endpoints were all-cause mortality and Kaplan-Meier estimated overall survival (OS) over 3 years. Secondary endpoints included cytokine release syndrome (CRS), hypogammaglobulinemia, neutropenia, other cytopenias, opportunistic infections, stem cell transplantation, and palliative care utilization.
Results
After 1:1 propensity score matching, 622 patients were included in each cohort (N=1,244). At 3 years, teclistamab was associated with lower all-cause mortality than PVd/carfilzomib-based therapy (19.0% vs 33.8%; HR 0.70, 95% CI 0.56–0.88; log-rank P=0.002). Estimated 3-year OS was 67.1% with teclistamab compared with 56.4% in the control cohort.
Patients treated with teclistamab had lower rates of palliative care utilization (15.4% vs 23.3%), opportunistic infections (37.8% vs 48.6%), and other cytopenias (49.2% vs 65.6%). Higher rates of expected treatment-related toxicities were observed with teclistamab, including CRS (20.9% vs 15.9%; HR 1.77, 95% CI 1.36–2.30), hypogammaglobulinemia (52.7% vs 34.4%; HR 2.48, 95% CI 2.08–2.96), and neutropenia (90.8% vs 87.1%; HR 2.22, 95% CI 1.97–2.51).
Conclusions
In this large propensity score-matched real-world analysis, teclistamab was associated with improved overall survival and lower all-cause mortality compared with standard pomalidomide- or carfilzomib-based regimens in patients with RRMM. Although CRS, hypogammaglobulinemia, and neutropenia occurred more frequently with teclistamab, these findings were observed alongside favorable survival outcomes and lower rates of opportunistic infections in this matched cohort. These results complement ongoing prospective studies and support the effectiveness of teclistamab in routine clinical practice.
DISCLOSURES
Zeeshan Solangi, MD: No relevant conflicts of interest to declare.